National Centre for Disease Prevention and Health Promotion, Istituto Superiore di Sanità - Italian National Institute of Health, Rome, Italy; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
National Centre for Disease Prevention and Health Promotion, Istituto Superiore di Sanità - Italian National Institute of Health, Rome, Italy.
Clin Microbiol Infect. 2023 Jun;29(6):772-780. doi: 10.1016/j.cmi.2023.01.013. Epub 2023 Jan 21.
OBJECTIVES: Evidence on the effects of the SARS-CoV-2 Omicron variant on vaccinated and unvaccinated pregnant women is sparse. This study aimed to compare maternal and perinatal outcomes of women infected with SARS-CoV-2 during the Omicron wave in Italy, according to their vaccine protection. METHODS: This national prospective cohort study enrolled pregnant women with a positive SARS-CoV-2 nasopharyngeal swab within 7 days of hospital admission between 1 January and 31 May, 2022. Women who received at least one dose of vaccine during pregnancy and those who completed the vaccine cycle with the first booster were considered protected against moderate or severe COVID-19 (MSCD). A multivariable logistic regression model evaluated the association between vaccine protection and disease severity. Maternal age, educational level, citizenship, area of birth, previous comorbidities, and obesity were analysed as potential risk factors. RESULTS: MSCD was rare (41/2147, 1.9%; 95% CI, 1.4-2.6), and the odds of developing it were significantly higher among unprotected women (OR, 2.78; 95% CI, 1.39-5.57). Compared with protected women (n = 1069), the unprotected (n = 1078) were more often younger, with lower educational degrees, and foreigners. A higher probability of MSCD was found among women with previous comorbidities (OR, 2.86; 95% CI, 1.34-6.12) and those born in Asian countries (OR, 3.05; 95% CI, 1.23-7.56). The percentage of preterm birth was higher among women with MSCD compared with milder cases (32.0% [8/25] versus 8.4% [161/1917], p < 0.001) as well as the percentage of caesarean section (52.0% [13/25] versus 31.6% [606/1919], p 0.029). DISCUSSION: Although severe maternal and perinatal outcomes were rare, their prevalence was significantly higher among women without vaccine protection. Vaccination during pregnancy has the potential to protect both the mother and the baby, and it is therefore strongly recommended.
目的:关于 SARS-CoV-2 奥密克戎变异株对已接种和未接种疫苗的孕妇影响的证据很少。本研究旨在比较意大利奥密克戎浪潮期间感染 SARS-CoV-2 的孕妇的母婴结局,根据她们的疫苗保护情况进行比较。
方法:本项全国前瞻性队列研究纳入了 2022 年 1 月 1 日至 5 月 31 日期间住院 7 天内鼻咽拭子 SARS-CoV-2 检测阳性的孕妇。在怀孕期间至少接种过一剂疫苗或完成第一剂加强针疫苗接种的女性被认为可预防中度或重度 COVID-19(MSCD)。多变量逻辑回归模型评估了疫苗保护与疾病严重程度之间的关联。分析了母亲年龄、教育程度、国籍、出生地、既往合并症和肥胖等作为潜在危险因素。
结果:MSCD 发生率较低(41/2147,1.9%;95%CI,1.4-2.6),未受保护的女性发生 MSCD 的几率明显更高(OR,2.78;95%CI,1.39-5.57)。与受保护的女性(n=1069)相比,未受保护的女性(n=1078)更年轻,教育程度更低,且为外国人。有既往合并症的女性发生 MSCD 的可能性更高(OR,2.86;95%CI,1.34-6.12),且来自亚洲国家的女性发生 MSCD 的可能性更高(OR,3.05;95%CI,1.23-7.56)。与轻症病例相比,MSCD 病例中早产儿比例更高(32.0%[8/25]与 8.4%[161/1917],p<0.001),剖宫产比例也更高(52.0%[13/25]与 31.6%[606/1919],p0.029)。
讨论:尽管严重的母婴结局罕见,但在未接种疫苗的女性中,其发生率明显更高。孕妇接种疫苗有可能保护母婴双方,因此强烈建议接种疫苗。
Am J Obstet Gynecol. 2024-10
Am J Obstet Gynecol. 2022-2
Ultrasound Obstet Gynecol. 2022-7
Am J Obstet Gynecol MFM. 2022-7
JAMA Netw Open. 2023-11-1
BMC Pregnancy Childbirth. 2022-2-28
Can J Infect Dis Med Microbiol. 2025-6-24
Public Health Pract (Oxf). 2024-3-25
BMJ. 2022-8-10
Microorganisms. 2022-7-15
N Engl J Med. 2022-7-14